Article Figures & Data
Figures
- FIGURE 1.
Waterfall plot demonstrating percentage change in PSA levels after treatment with 225Ac-PSMA-617 in patient cohort (x-axis = number of patients; y-axis = percentage change).
- FIGURE 2.
Kaplan–Meier curves of PSA-based OS of the entire cohort (PSA decline of ≥ 50% [green curve] and percentage of PSA decline < 50% [blue curve]) (A), PFS of the entire cohort (PSA decline of ≥ 50% [green curve] and percentage of PSA decline < 50% [blue curve]) (B), and PFS stratified by platelet counts (platelet counts < 293,000/mL [blue curve] and platelet counts > 293,000 [green curve]) (C).
Tables
Characteristic Value No. of patients included 53 Median age (y) 63.4 Eastern Cooperative Oncology Group score of 0 or 1 (n) 42 Eastern Cooperative Oncology Group score of 2 (n) 11 Median PSA level (ng/mL) 466 Median alkaline phosphatase level (IU/L) 188 Median hemoglobin value (g/dL) 11.5 Bone metastases (n) 47 Lymph node metastases (n) 36 Visceral metastases (n) 6 Lung 1 Liver 5 Brain 1 Local therapy to prostate (n) Prostatectomy 31 Radiotherapy 11 No local therapy 11 Characteristic Grade I–II Grade III Grade IV Xerostomia 43 (81%) 0 0 Anemia 7 (13%) 1 (2%) 0 Leukopenia 4 (7%) 1 (2%) 0 Thrombocytopenia 5 (9%) 0 0 Renal failure 7 (13%) 2 (4%) 1 (2%) Variable PFS OS Age 0.180 0.748 Eastern Cooperative Oncology Group score 0.077 0.772 Gleason score 0.596 0.774 Previous local radiotherapy 0.304 0.916 Baseline PSA level 0.972 0.888 PSA ≥ 50% decline <0.001* <0.001* PSA undetectable 0.014* 0.132 Visceral metastases 0.937 0.772 Lymph node involvement 0.289 0.942 Bone metastases 0.459 0.186 No. of treatment cycles 0.650 0.097 ALP 0.727 0.886 Hemoglobin 0.090 0.132 Platelet count 0.041* 0.602 White blood cell count 0.373 0.605 Radiologic response 0.006* 0.407 PSMA-negative 0.026* 0.418 ↵* P < 0.05.
